EG24936A - Acetylene derivatives having MGLUR 5 antagonistic activity - Google Patents

Acetylene derivatives having MGLUR 5 antagonistic activity

Info

Publication number: EG24936A
Authority: EG; Egypt
Prior art keywords: mglur; antagonistic activity; acetylene derivatives; acetylene; derivatives
Prior art date: 2001-12-04

Application number

EG2002121297A

Other languages

English (en)

Inventor

Fabrizio Gasparini

Yves Auberson

Silvio Ofner

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-04

Filing date

2002-12-01

Publication date

2011-01-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9926969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EG24936(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-12-01 Application filed by Novartis Ag filed Critical Novartis Ag

2011-01-11 Application granted granted Critical

2011-01-11 Publication of EG24936A publication Critical patent/EG24936A/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/23—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/08—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Addiction (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Indole Compounds (AREA)
Quinoline Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)

EG2002121297A 2001-12-04 2002-12-01 Acetylene derivatives having MGLUR 5 antagonistic activity EG24936A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0128996.6A GB0128996D0 (en)	2001-12-04	2001-12-04	Organic compounds

Publications (1)

Publication Number	Publication Date
EG24936A true EG24936A (en)	2011-01-11

Family

ID=9926969

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EG2002121297A EG24936A (en)	2001-12-04	2002-12-01	Acetylene derivatives having MGLUR 5 antagonistic activity

Country Status (31)

Country	Link
US (4)	US7348353B2 (xx)
EP (1)	EP1453512B8 (xx)
JP (2)	JP4176020B2 (xx)
KR (2)	KR100980901B1 (xx)
CN (2)	CN101366714B (xx)
AR (2)	AR037682A1 (xx)
AT (1)	ATE327755T1 (xx)
AU (1)	AU2002358585B2 (xx)
BR (1)	BR0214666A (xx)
CA (1)	CA2466560C (xx)
CO (1)	CO5590929A2 (xx)
CY (1)	CY1105460T1 (xx)
DE (1)	DE60211944T2 (xx)
DK (1)	DK1453512T3 (xx)
EC (1)	ECSP045139A (xx)
EG (1)	EG24936A (xx)
ES (1)	ES2263842T3 (xx)
GB (1)	GB0128996D0 (xx)
HU (1)	HU229429B1 (xx)
IL (1)	IL161990A0 (xx)
MX (1)	MXPA04005456A (xx)
MY (1)	MY137774A (xx)
NO (1)	NO327005B1 (xx)
NZ (1)	NZ533266A (xx)
PE (1)	PE20030640A1 (xx)
PL (1)	PL212996B1 (xx)
PT (1)	PT1453512E (xx)
RU (1)	RU2341515C2 (xx)
TW (1)	TWI328578B (xx)
WO (1)	WO2003047581A1 (xx)
ZA (1)	ZA200403713B (xx)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0128996D0 (en) *	2001-12-04	2002-01-23	Novartis Ag	Organic compounds
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
GB0325956D0 (en) *	2003-11-06	2003-12-10	Addex Pharmaceuticals Sa	Novel compounds
US20080125403A1 (en)	2004-04-02	2008-05-29	Merck & Co., Inc.	Method of Treating Men with Metabolic and Anthropometric Disorders
GB0503646D0 (en) *	2005-02-22	2005-03-30	Novartis Ag	Organic compounds
GB0508318D0 (en) *	2005-04-25	2005-06-01	Novartis Ag	Organic compounds
GB0508319D0 (en) *	2005-04-25	2005-06-01	Novartis Ag	Organic compounds
GB0508314D0 (en) *	2005-04-25	2005-06-01	Novartis Ag	Organic compounds
GB0514296D0 (en) *	2005-07-12	2005-08-17	Novartis Ag	Organic compounds
KR20090061041A (ko) *	2006-09-11	2009-06-15	노파르티스 아게	대사성 글루타메이트 수용체의 조절제로서의 니코틴산 유도체
WO2008151257A2 (en)	2007-06-04	2008-12-11	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
BRPI0818560A2 (pt) *	2007-10-12	2019-09-24	Novartis Ag	compostos orgânicos
AU2012254934B2 (en) *	2007-10-12	2013-10-17	Novartis Ag	Metabotropic glutamate receptor modulators for the treatment of Parkinson's disease
EP2810951B1 (en)	2008-06-04	2017-03-15	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2826478A1 (en) *	2008-06-30	2015-01-21	Novartis AG	Combinations comprising mglur modulators for the treatment of parkinson's disease
NZ590753A (en) *	2008-08-12	2012-06-29	Novartis Ag	Processes for the preparation of 4-oxo-octahydro-indole-1-carbocylic acid methyl ester and derivatives thereof
US8334287B2 (en)	2009-07-17	2012-12-18	Hoffmann-La Roche Inc.	Imidazoles
WO2011009890A2 (en)	2009-07-23	2011-01-27	Novartis Ag	Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives
JO3250B1 (ar)	2009-09-22	2018-09-16	Novartis Ag	إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
EP2490691A1 (en)	2009-10-20	2012-08-29	Novartis AG	Use of 1h-quinazoline-2,4-diones
BR112012027816A2 (pt) *	2010-04-30	2017-08-08	Novartis Ag	marcadores preditivos úteis no tratamento da síndrome do x frágil (fxs).
RU2013103001A (ru)	2010-06-24	2014-07-27	Новартис Аг	Применение 1н-хиназолин-2,4-дионов
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
US20130274294A1 (en) *	2010-12-20	2013-10-17	David Carcache	4-(Hetero)Aryl-Ethynyl-Octahydro-Indole-1-Esters
EP2668159A1 (en)	2011-01-24	2013-12-04	Novartis AG	4-tolyl-ethynyl-octahydro-indole-1-ester derivatives
US20140171448A1 (en)	2011-01-27	2014-06-19	Novartis Ag	Use of nicotinic acetylcholine receptor alpha 7 activators
CA2830458A1 (en)	2011-03-18	2012-09-27	Novartis Ag	Combinations of alpha 7 nicotinic acetylcholine receptor activators and mglur5 antagonists for use in dopamine induced dyskinesia in parkinson's disease
WO2013036224A1 (en)	2011-09-07	2013-03-14	Novartis Ag	Use of 1h-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy
WO2013131981A1 (en)	2012-03-08	2013-09-12	Novartis Ag	Predictive markers useful in the diagnosis and treatment of fragile x syndrome (fxs)
GB201215033D0 (en)	2012-08-23	2012-10-10	Novartis Ag	Diazepinone derivatives
BR112015016994A8 (pt)	2013-01-15	2018-01-23	Novartis Ag	uso de agonistas do receptor alfa 7 nicotínico de acetilcolina
WO2014111837A1 (en)	2013-01-15	2014-07-24	Novartis Ag	Use of alpha 7 nicotinic acetylcholine receptor agonists
US9708367B2 (en)	2013-03-15	2017-07-18	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase and their uses
AU2014235209B2 (en)	2013-03-15	2018-06-14	Bausch Health Ireland Limited	Guanylate cyclase receptor agonists combined with other drugs
CN105764916B (zh)	2013-06-05	2021-05-18	博士医疗爱尔兰有限公司	鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
PL3007682T3 (pl) *	2013-06-12	2017-12-29	Novartis Ag	Formulacja o modyfikowanym uwalnianiu
GB201312800D0 (en)	2013-07-17	2013-08-28	Heptares Therapeutics Ltd	mGlu5 modulators
CN105669686B (zh) *	2014-11-19	2018-08-03	上海合全药业股份有限公司	一种6-(叔丁氧羰基)八氢呋喃[2,3-c]吡啶-4-羧酸的合成方法
CA3066711A1 (en)	2017-07-31	2019-02-07	Novartis Ag	Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
US12201612B2 (en)	2017-07-31	2025-01-21	Novartis Ag	Use of mavoglurant in the reduction of alcohol use or in preventing relapse into alcohol use
KR20210120011A (ko)	2019-01-29	2021-10-06	노파르티스 아게	오피오이드 진통제 내약성을 치료하기 위한 mglur5 길항제의 용도
US20220387410A1 (en) *	2019-11-05	2022-12-08	Claes Thulin	4-[5-[(rac)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine for use in prevention and/or treatment of surmenage in a mammal
MX2023000664A (es)	2020-07-17	2023-02-27	Novartis Ag	Uso de antagonistas de mglur5.
WO2022123482A1 (en)	2020-12-11	2022-06-16	Novartis Ag	Use of mglur5 antagonists for treating amphetamine addiction
CA3204360A1 (en)	2020-12-14	2022-06-23	Novartis Ag	Use of mglur5 antagonists for treating gambling disorder

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2741009A1 (de) *	1976-09-22	1978-03-23	Sandoz Ag	4-styryl-4-indolinol-derivate, ihre verwendung und herstellung
DE2802833A1 (de)	1978-01-23	1979-07-26	Sandoz Ag	4-styryl-4-indolinol-derivate, ihre verwendung und herstellung
US5264456A (en) *	1989-12-29	1993-11-23	Allergan, Inc.	Acetylenes disubstituted with a furyl group and a substituted phenyl group having retinoid like activity
US5284957A (en)	1992-09-03	1994-02-08	Eli Lilly And Company	Excitatory amino acid receptor antagonists
US5593994A (en)	1994-09-29	1997-01-14	The Dupont Merck Pharmaceutical Company	Prostaglandin synthase inhibitors
EP1304322A3 (en)	1995-08-22	2003-11-19	Japan Tobacco Inc.	Carboxylic acid compound and use thereof
WO1997048697A1 (en)	1996-06-19	1997-12-24	Rhone-Poulenc Rorer Limited	Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
TW544448B (en) *	1997-07-11	2003-08-01	Novartis Ag	Pyridine derivatives
EP1085010B1 (en) *	1998-06-04	2004-03-10	Kumiai Chemical Industry Co., Ltd.	Phenylacetylene derivatives and agricultural/horticultural bactericides
PT1117403E (pt)	1998-10-02	2004-04-30	Sibia Neurosciences Inc	Antagonistas de mglurs para o tratamento da dor e ansiedade
IL146697A0 (en)	1999-07-06	2002-07-25	Lilly Co Eli	SELECTIVE iGluR5 RECEPTOR FOR THE TREATMENT OF MIGRAINE
GB0007108D0 (en)	2000-03-23	2000-05-17	Novartis Ag	Organic compounds
NZ526003A (en)	2000-10-20	2005-09-30	Biocryst Pharm Inc	Biaryl compounds as serine protease inhibitors
RS43903A (sr) *	2000-12-04	2006-12-15	F.Hoffmann-La Roche Ag.	Feniletenil-ili feniletinil-derivati kao antagonisti glutamatnih receptora
GB0103045D0 (en)	2001-02-07	2001-03-21	Novartis Ag	Organic Compounds
US7138404B2 (en)	2001-05-23	2006-11-21	Hoffmann-La Roche Inc.	4-aminopyrimidine derivatives
BR0214642A (pt)	2001-12-04	2004-11-03	Hoffmann La Roche	Compostos, métodos para a preparação de um composto, composições farmacêuticas que compreendem o mesmo e método para o tratamento e/ou prevenção de enfermidades que estão associadas com protéases de cisteìna e utilização desses compostos
TW200303309A (en)	2001-12-04	2003-09-01	Bristol Myers Squibb Co	Novel n-[4-(1h-imidazol-1-yl)-2-fluorophenyl]-3-trifluoromethyl)-1h-pyrazole-5-carboxamides as factor Xa inhibitors
GB0128996D0 (en) *	2001-12-04	2002-01-23	Novartis Ag	Organic compounds

2001
- 2001-12-04 GB GBGB0128996.6A patent/GB0128996D0/en not_active Ceased
2002
- 2002-12-01 EG EG2002121297A patent/EG24936A/xx active
- 2002-12-02 AR ARP020104641A patent/AR037682A1/es not_active Application Discontinuation
- 2002-12-02 PE PE2002001157A patent/PE20030640A1/es not_active Application Discontinuation
- 2002-12-02 TW TW091134933A patent/TWI328578B/zh not_active IP Right Cessation
- 2002-12-03 KR KR1020107002745A patent/KR100980901B1/ko not_active Expired - Fee Related
- 2002-12-03 KR KR1020047008477A patent/KR100959204B1/ko not_active Expired - Fee Related
- 2002-12-03 JP JP2003548836A patent/JP4176020B2/ja not_active Expired - Lifetime
- 2002-12-03 ES ES02792867T patent/ES2263842T3/es not_active Expired - Lifetime
- 2002-12-03 AU AU2002358585A patent/AU2002358585B2/en not_active Ceased
- 2002-12-03 BR BR0214666-5A patent/BR0214666A/pt not_active Application Discontinuation
- 2002-12-03 DE DE60211944T patent/DE60211944T2/de not_active Expired - Lifetime
- 2002-12-03 EP EP02792867A patent/EP1453512B8/en not_active Expired - Lifetime
- 2002-12-03 WO PCT/EP2002/013670 patent/WO2003047581A1/en not_active Ceased
- 2002-12-03 RU RU2004120781/04A patent/RU2341515C2/ru not_active IP Right Cessation
- 2002-12-03 MX MXPA04005456A patent/MXPA04005456A/es active IP Right Grant
- 2002-12-03 PT PT02792867T patent/PT1453512E/pt unknown
- 2002-12-03 US US10/497,363 patent/US7348353B2/en not_active Expired - Lifetime
- 2002-12-03 CN CN200810166366.0A patent/CN101366714B/zh not_active Expired - Lifetime
- 2002-12-03 NZ NZ533266A patent/NZ533266A/en not_active IP Right Cessation
- 2002-12-03 DK DK02792867T patent/DK1453512T3/da active
- 2002-12-03 CN CNB028232968A patent/CN100430059C/zh not_active Expired - Lifetime
- 2002-12-03 IL IL16199002A patent/IL161990A0/xx not_active IP Right Cessation
- 2002-12-03 PL PL368739A patent/PL212996B1/pl unknown
- 2002-12-03 CA CA2466560A patent/CA2466560C/en not_active Expired - Fee Related
- 2002-12-03 MY MYPI20024525A patent/MY137774A/en unknown
- 2002-12-03 AT AT02792867T patent/ATE327755T1/de active
- 2002-12-03 HU HU0402191A patent/HU229429B1/hu unknown
2004
- 2004-05-14 ZA ZA2004/03713A patent/ZA200403713B/en unknown
- 2004-06-04 EC EC2004005139A patent/ECSP045139A/es unknown
- 2004-06-07 CO CO04053105A patent/CO5590929A2/es active IP Right Grant
- 2004-06-25 NO NO20042673A patent/NO327005B1/no not_active IP Right Cessation
2006
- 2006-08-03 CY CY20061101091T patent/CY1105460T1/el unknown
2008
- 2008-02-29 US US12/040,081 patent/US20080146647A1/en not_active Abandoned
- 2008-07-09 JP JP2008179005A patent/JP5036648B2/ja not_active Expired - Lifetime
2011
- 2011-09-22 US US13/239,467 patent/US8536229B2/en not_active Expired - Lifetime
2012
- 2012-11-20 AR ARP120104356A patent/AR088921A2/es not_active Application Discontinuation
2013
- 2013-08-15 US US13/967,719 patent/US20130331568A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20080146647A1 (en)	2008-06-19
ES2263842T3 (es)	2006-12-16
CO5590929A2 (es)	2005-12-30
EP1453512B1 (en)	2006-05-31
NZ533266A (en)	2005-02-25
WO2003047581A1 (en)	2003-06-12
DK1453512T3 (da)	2006-08-28
MXPA04005456A (es)	2004-10-11
HU229429B1 (en)	2013-12-30
EP1453512B8 (en)	2006-07-19
CN101366714B (zh)	2014-09-17
JP2005514381A (ja)	2005-05-19
US8536229B2 (en)	2013-09-17
BR0214666A (pt)	2004-11-03
ECSP045139A (es)	2004-07-23
PE20030640A1 (es)	2003-09-12
PL368739A1 (en)	2005-04-04
KR100959204B1 (ko)	2010-05-19
AR088921A2 (es)	2014-07-16
ZA200403713B (en)	2005-10-26
HUP0402191A3 (en)	2010-03-29
AR037682A1 (es)	2004-12-01
AU2002358585A1 (en)	2003-06-17
ATE327755T1 (de)	2006-06-15
CA2466560A1 (en)	2003-06-12
JP2008303226A (ja)	2008-12-18
NO327005B1 (no)	2009-04-06
US20130331568A1 (en)	2013-12-12
US20050065191A1 (en)	2005-03-24
PT1453512E (pt)	2006-10-31
KR100980901B1 (ko)	2010-09-07
IL161990A0 (en)	2005-11-20
TWI328578B (en)	2010-08-11
US7348353B2 (en)	2008-03-25
TW200304910A (en)	2003-10-16
RU2341515C2 (ru)	2008-12-20
HUP0402191A2 (hu)	2005-02-28
CN100430059C (zh)	2008-11-05
JP4176020B2 (ja)	2008-11-05
EP1453512A1 (en)	2004-09-08
DE60211944T2 (de)	2007-05-16
CN1592623A (zh)	2005-03-09
US20120010263A1 (en)	2012-01-12
DE60211944D1 (de)	2006-07-06
KR20050044657A (ko)	2005-05-12
JP5036648B2 (ja)	2012-09-26
CN101366714A (zh)	2009-02-18
GB0128996D0 (en)	2002-01-23
RU2004120781A (ru)	2006-01-10
CA2466560C (en)	2010-07-27
NO20042673L (no)	2004-06-25
CY1105460T1 (el)	2010-04-28
HK1071510A1 (en)	2005-07-22
PL212996B1 (pl)	2012-12-31
AU2002358585B2 (en)	2006-01-19
KR20100020044A (ko)	2010-02-19
MY137774A (en)	2009-03-31

Publication	Publication Date	Title
EG24936A (en)	2011-01-11	Acetylene derivatives having MGLUR 5 antagonistic activity
IL169378A0 (en)	2007-07-04	Benzoazolypiperazine derivatives having vr1 antagonistic activity
TW595857U (en)	2004-06-21	091219345
HUP0402171A3 (en)	2008-08-28	Pyrazolopyrimidinone derivatives having pde7-inhibitory activity
AU148186S (en)	2002-06-17	Sprinkler
MXPA03008216A (es)	2004-01-29	Derivados de 3-fenilo.
AU2002312371A1 (en)	2002-12-23	Aryl-benzimidazole compounds having antiinfective activity
DE60223679D1 (en)	2008-01-03	Sprinkler
AU2003257651A1 (en)	2004-03-11	4'-thionucleotide
IL142732A0 (en)	2002-03-10	Sprinklers
SI1453512T1 (sl)	2006-10-31	Derivati etina z antagonisticnim delovanjem na MGLUR 5
IL154920A0 (en)	2003-10-31	Delta 1-pyrrollines for use as pesticides
AU2003255737A8 (en)	2004-02-16	Antimicrobial 2, 4-diamino-pteridine derivatives
IL159965A0 (en)	2004-06-20	Novel 2,4-diaminothiazole derivatives
PL370505A1 (en)	2005-05-30	Substituted 1,5-diaminopentan-3-ol compounds
AU2002234465A1 (en)	2002-09-04	1,2-diphenyl-1-naphthyl ethene derivatives, analogs and use thereof
IL141781A0 (en)	2002-03-10	Regulated sprinkler
GB0115562D0 (en)	2001-08-15	None given on form 1/77
GB0118178D0 (en)	2001-09-19	July 24
GB0118177D0 (en)	2001-09-19	July 25
TW539396U (en)	2003-06-21	090220607
TW539394U (en)	2003-06-21	090212946
GB0118917D0 (en)	2001-09-26	Biopower 3
GB0118315D0 (en)	2001-09-19	Jackit 31
GB0116704D0 (en)	2001-08-29	Unistore 800